The use of anti-depressant medication has been linked to cardiovascular disease (CVD). We examined the association between anti-depressant medication use and a marker of low grade systemic inflammation as a potential pathway linking anti-depressant use and CVD in two population based studies. Data were collected in a representative sample of 8131 community dwelling adults (aged 47.4 ± 15.9 years, 46.7% male) from the Scottish Health Surveys (SHS). The use of anti-depressant medication was coded according to the British National Formulary and blood was drawn for the measurement of C-reactive protein (CRP). In a second study, we attempted to replicate our findings using longitudinal data from the Whitehall II study (n = 4584, aged 55.5 ± 5.9 years, mean follow-up 5.5 years). Antidepressants were used in 5.6% of the SHS sample, with selective serotonin reuptake inhibitors (SSRIs) being the most common. There was a higher risk of elevated CRP (>3 mg/L) in users of tricyclic antidepressant (TCA) medication (multivariate adjusted odds ratio (OR) = 1.52, 95% CI, 1.07-2.15), but not in SSRI users (multivariate adjusted OR = 1.07, 95% CI, 0.81-1.42). A longitudinal association between any antidepressant use and subsequent CRP was confirmed in the Whitehall cohort. In summary, the use of anti-depressants was associated with elevated levels of systemic inflammation independently from the symptoms of mental illness and cardiovascular co-morbidity. This might be a potential mechanism through which antidepressant medication increases CVD risk. Further data are required to explore the effects of dosage and duration of antidepressant treatment.
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Introduction
As a result of the secular rises in mental health problems, antidepressant medication is currently commonly prescribed across Europe and the United States (Olfson and Marcus, 2009; Reid and Barbui, 2010) . The use of anti-depressant medication has been linked with a greater risk of weight gain (Aronne and Segal, 2003) , diabetes (Rubin et al., 2008; Andersohn et al., 2009; Kivimä-ki et al., 2010) , and with an increased risk of cardiovascular disease (CVD) events in most (Cohen et al., 2000; Tata et al., 2005; Chen et al., 2008; Fosbøl et al., 2009; Krantz et al., 2009; Smoller et al., 2009 ), but not all (Taylor et al., 2005; Knol et al., 2007; O'Connor et al., 2008) studies. Low grade systemic inflammatory processes may be a key mechanism underlying some of the potential adverse effects of anti-depressant medication, particularly raised CVD risk.
While a series of studies suggest an association between depressive symptoms and higher levels of inflammatory biomarkers (Dinan, 2009) , the link between anti-depressant use and inflammation has not been previously tested in a large sample of the general population.
The aim of the present study was therefore to examine the association between anti-depressant medication use and C-reactive protein (CRP) in a representative sample of community dwelling adults. Additionally, we performed a replication study based on longitudinal data from the Whitehall II cohort.
Methods

Scottish Health Survey
The Scottish Health Survey is a cross-sectional study that is typically conducted serially every 3-5 years, that draws a different nationally representative sample of the general population living in households for each survey (see Scottish Health Survey Publications). For the present analysis we combined data from
